Final Programme


Poster Session Online


ERA-EDTA Congress 2012
Scientific Programme
Preliminary Scientific Programme
• The novel endocrinology of bone
Gerard Karsenty, New York, USA
• Fructose, metabolic syndrome and kidney disease
Richard Johnson, Denver, USA

• Novel insights into the renal handling of calcium and magnesium
René Bindels, Nijmegen, Netherlands

• The Medullary Sponge Kidney: a still misunderstood nephropathy
Giovanni Gambaro, Rome, Italy

• Genetic animal models for primary hyperoxaluria
Eduardo Salido, Tenerife, Spain

• ATP and the kidney
Robert J. Unwin, London, UK

• Presentation of EU-funded consortia in nephrology
Carsten Wagner, Zurich, Switzerland

• An analysis of the worldwide output in Nephrology research 2002-2010
Marc de Broe, Antwerp, Belgium
• Epidemiology of AKI in the ICU
Fernando Liaño, Madrid, Spain

• Is AKI a risk factor for CKD and ESRD
Norbert Lameire, Ghent, Belgium

• The vascular access unit: surgeons, nephrologists, nurses or all of them together?
Carlo Basile, Taranto, Italy

• What have we learnt from the CONTRAST study (on convective removal in dialysis)
Peter Blankestijn, Utrecht, Netherlands

• Disaster nephrology
Mehmet Sukru Sever, Istanbul, Turkey

• Modulators of positive and negative costimulation
Bernard Vanhove, Nantes, France

• Weight changes before and after renal transplantation - is it relevant?
Magdalena Durlik, Warsaw, Poland

• Stem cell therapy using MSC from human adipose tissues
Shoichi Maruyama, Nagoya, Japan

• Podocyte cell communication through glutamate receptors and co
Maria Pia Rastaldi, Milan, Italy

• Intrarenal Renin Angiotensin System
Laszlo Rosivall, Budapest, Hungary

• Balkan nephropathy - new insights
Bojan Jelakovic, Zagreb, Croatia

Will urinary proteomics make the renal tissue biopsy redundant?
Loreto Gesualdo, Bari, Italy


Clinical nephrology
Eberhard Ritz, Heidelberg, Germany
Dominique Joly, Paris, France

CKD & Dialysis
Carmine Zoccali, Reggio Calabria, Italy
Tilman Drueke, Amiens, France

Daniel Abramowicz, Brussels, Belgium
Denis Glotz, Paris, France

Fluid and electrolytes, tubular transport, physiology

Advances in understanding tubular function
- Molecular pathophysiology of renal magnesium handling
Joost G.J. Hoenderop, Nijmegen, Netherlands
- Cubilin and tubular function
Erik Ilsø Christensen, Aarhus, Denmark
- Renal TRPathies
Thomas Gudermann, Munich, Germany
- Role of parvalbumin in the distal tubule
Olivier Devuyst, Zurich, Switzerland

Glomerular permeability and permeability-inducing factors
- Electrical effects across the glomerular filtration barrier
Marcus J. Moeller, Aachen, Germany
- Podocytes, the filtration barrier and glomerular permeability
Tobias Huber, Freiburg, Germany
- c-mip and idiopathic nephrotic syndrome
Dil Sahali, Créteil, France
- The role of the glomerular endothelial barrier
Börje Haraldsson, Gothenburg, Sweden

Advances in understanding the renin-angiotensin system
- Aldosterone synthase inhibition
Michel Azizi, Paris, France
- Prorenin receptor function in the kidney
Geneviève Nguyen, Paris, France
- Renin-Inhibitors: What is their current place in therapy?
Jan Danser, Rotterdam, Netherlands

Calcium sensing and PTH secretion
- Physiology and pathophysiology of the calcium sensing receptor in the kidney
Daniela Riccardi, Cardiff, UK
- microRNAs and RNA binding proteins in the regulation of PTH synthesis
Tally Naveh-Many, Jerusalem, Israel
- Calcium sensing receptor: extrarenal effects
Dominique Prié, Paris, France
- Modulation of calcium sensing by calcimimetics
J. Mariano Rodriguez, Cordoba, Spain

Stem cells
- Stem cells and renal repair
Ariela Benigni, Bergamo, Italy
- Endogenous stem cells of the kidney
Paola Romagnani, Florence, Italy
- Stem cell function in the uremic milieu
Uta Kunter, Aachen, Germany

Hyponatremia (ERBP guideline session)
- The pathophysiology and symptoms of hyponatremia
Peter Gross, Dresden, Germany
- Diagnostic approach to hyponatremia: the ERBP point of view
Robert Zietse, Rotterdam, Netherlands
- Treatment of hyponatremia
Michael Joannidis, Innsbruck, Austria

Hereditary disorders, development, pregnancy, paediatric nephrology

Ciliopathies and polycystic kidney disease (basic and translational)
- HNF1beta, cystic kidneys and morphogenesis
Marco Pontoglio, Paris, France
- Regulation of mTOR signalling by cilia and flow
Wolfgang Kuehn, Freiburg, Germany
- Ciliopathies / BBS
Nicholas Katsanis, Durham, USA
- Are animal models suitable for testing therapies applicable to humans?
Dorien Peters, Leiden, Netherlands

Polycystic kidney disease: clinical studies
- Vaptans in ADPKD
Vicente Torres, Rochester, USA
- Somatostatin analogues in polycystic liver disease
Joost P.H. Drenth, Nijmegen, Netherlands
- What is a reasonable endpoint in clinical PKD studies?
Giuseppe Remuzzi, Bergamo, Italy
The many masks of HNF1beta-related (kidney) diseases
Dominique Chauveau, Toulouse, France

Renal cancer and the kidney in cancer
- The role of miRNA in RCC
Elena Ranieri, Foggia, Italy
- VHL tumor suppressor protein and longevity
Roman-Ulrich Müller, Cologne, Germany
- The dilemma of early treatment of angiomyolipomas
John Bissler, Cincinnati, USA

Thrombotic microangiopathies and complement disorders
- EHEC: the German 2011 epidemic
Jan T. Kielstein, Hanover, Germany
- Atypical HUS and the complement system
Véronique Fremeaux-Bacchi, Paris, France
- The biology of ADAMs in renal diseases
Harry Van Goor, Groningen, Netherlands
- C3 glomerulonephritis and CFHR5 nephropathy
Patrick Maxwell, London, UK

Genetic diseases of the glomerular barrier

- The cytoskeleton and FSGS
Marina Noris, Bergamo, Italy
- A new protein mutated in glomerular disease and neuropathy
Corinne Antignac, Paris, France
- COL4A1 related disorders in mice and men
Emmanuelle Plaisier, Paris, France
- Molecular genetics of familial hematuric diseases
Constantinos Deltas, Nicosia, Cyprus

Glomerular diseases and general clinical nephrology

Late Breaking Clinical Trials

Leukocytes and pro-inflammatory mediators in renal injury
- Genetic loci modulate macrophage activity in glomerulonephritis
Terry Cook, London, UK
- Kidney dendritic cells in acute and chronic renal disease
Christian Kurts, Bonn, Germany
- Kinase inhibitors in experimental glomerulonephritis
Charles Pusey, London, UK
- NFκB in renal inflammation
Alberto Ortiz, Madrid, Spain

Minimal Change Disease / FSGS
- Minimal change nephropathy: the search for molecular mediators
Sumant Singh Chugh, Birmingham, USA
- FSGS: the search for permeability factors
Jochen Reiser, Miami, USA
- When to start a genetic study in a patient with FSGS?
Roser Torra, Barcelona, Spain
- Which treatment for steroid dependent nephrotic syndrome in children?”
Patrick Niaudet, Paris, France

Membranous Nephropathy
- Recent advances in the pathogenesis of membranous nephropathy
Hanna Debiec, Paris, France
- PLA2-Receptor antibodies and their role in the monitoring of treatment of membranous nephropathy
Rolf A.K. Stahl, Hamburg, Germany
- Spontaneous remission of nephrotic syndrome in membranous nephropathy
Manuel Praga, Madrid, Spain
- KDIGO Guidelines: Treatment of membranous nephropathy
Jack F.M. Wetzels, Nijmegen, Netherlands

IgA Nephropathy
- Pathogenesis of IgA Nephropathy: new insights
John Feehally, Leicester, UK
- VALIGA: the largest clinical and pathological database for IgA nephropathy in Europe
Rosanna Coppo, Turin, Italy
- IgAN - a mucosal immune disease?
Bengt Fellström, Uppsala, Sweden
- KDIGO Guidelines: Indications for immunosuppressive therapy in IgA Nephropathy
Jürgen Floege, Aachen, Germany

Vasculitis and lupus
- Unravelling ANCA vasculitis mechanisms using animal models
Ralph Kettritz, Berlin, Germany
- Lupus nephritis: the role of extracellular matrix and chemokines
Liliana Schaefer, Frankfurt am Main, Germany
- Recent advances in the treatment of ANCA-positive vasculitis
Wladimir M. Szpirt, Copenhagen, Denmark
- Recent advances in the treatment of lupus nephritis
Vladimir Tesar, Prague, Czech Republic

Paraneoplastic GN, monoclonal-IgG related disorders and amyloid
- Glomerulonephritis with monoclonal immunoglobulin deposits: the expanding spectrum
Alexandre Karras, Paris, France
- Recent diagnostic and therapeutic advances in ALamyloidosis
Frank Bridoux, Poitiers, France
- New strategies for the treatment of amyloidosis
Mark B. Pepys, London, UK

Albuminuria and other biomarkers
- Albuminuria as predictor of poor renal and CV outcome
Paul de Jong, Groningen, Netherlands
- Albuminuria - a limb of the new KDIGO CKD tripod
Christopher G. Winearls, Oxford, UK
- Finding protein biomarkers in urinary exosomes: application of principles from systems biology
Mark A. Knepper, Bethesda, USA
- Transcriptional networks in glomerular failure
Matthias Kretzler, Ann Arbor, USA

Acute kidney injury and intensive care nephrology

New advances in the pathophysology of AKI
- Protection of mitochondria: new target to prevent nephrotoxicity
Dmitry B. Zorov, Moscow, Russia
- NGAL: more than a marker of AKI
Jonathan Barasch, New York, USA
- The role of complement in the pathogenesis of ischemia-reperfusion damage
Giuseppe Grandaliano, Foggia, Italy

Prevention of AKI and delayed graft function
- Abnormal oxygen metabolism in uremia
Masaomi Nangaku, Tokyo, Japan
- Prevention of renal injury through upregulation of HIF
Kai-Uwe Eckardt, Erlangen, Germany
- Ischemic preconditioning
Mohammad Magdi Yaqoob, London, UK
- Machine-perfusion of kidney allografts
Rutger J. Ploeg, Oxford, UK

Sepsis and AKI
- Diagnosis and treatment of hyponatremia in the ICU - the ERBP guideline
Evi Nagler, Ghent, Belgium
- General, non-renal management of septic shock
Eric Hoste, Ghent, Belgium
- CRRT in sepsis, does the anticogulant matter?
Heleen M. Oudemans-van Straaten, Amsterdam, Netherlands
- SLED vs CRRT vs IHD in sepsis
Achim Jörres, Berlin, Germany

CKD - epidemiology, prevention, progression, pathophysiology

Renal Fibrosis
- The development of tubulo-interstitial fibrosis
Wilhelm Kriz, Mannheim, Germany
- Lipocalin-2 and progression of CKD
Fabiola Terzi, Paris, France
- EGF receptor pathway and progression of glomerular disease
Pierre-Louis Tharaux, Paris, France
- Methylation determines fi broblast activation and fibrogenesis in the kidney
Michael Zeisberg, Göttingen, Germany

Vascular calcification in CKD

- Vascular calcifications – lessons from animal studies
Patrick D’Haese, Antwerp, Belgium
- Magnesium and cardiovascular disease in CKD
Fatih Kircelli, Izmir, Turkey
- The mysterious effects of sodium thiosulfate on extraosseous calcifications
Andreas Pasch, Bern, Switzerland
- Vascular calcification in patients with CKD. Outcomes and therapy
Teresa Adragao, Cascais, Portugal

Current aspects of CKD-mineral bone disorders
- Cardiovascular disease related mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals
Michal Nowicki, Lodz, Poland
- Not all phosphate is created equal: phosphate toxicity by food supplements?
Markus Ketteler, Coburg, Germany
- Interaction between FGF23, PTH, P and calcitriol in CKD-MBD, which comes first?
Justin Silver, Jerusalem, Israel
- Vitamin D, FGF23 and innate immunity in CKD
Justine Bacchetta, Bron, France

Markers of renal progression - New approaches and studies

- Systems biology: building a useful model from multiple markers and profiles
Gert Mayer, Innsbruck, Austria
- Genome-wide association studies in CKD
Murielle Bochud, Epalinges, Switzerland
- The French CKD-REIN cohort study
Bénédicte Stengel, Villejuif, France
- The BIND-NL cohort: a strategic initiative in CKD
Gerjan Navis, Groningen, Netherlands

Anaemia management
- How important is transfusion avoidance in 2012
Iain C. Macdougall, London, UK
- Can we predict the risk for adverse events?
Andrzej Wiecek, Katowice, Poland
- Anaemia management: the KDIGO recommendations
Patrick S. Parfrey, St. John’s, Canada
- Anaemia management: how and why does ERBP differ from KDIGO
Francesco Locatelli, Lecco, Italy

Management issues in patients with CKD

- New uraemic toxins
Griet Glorieux, Ghent, Belgium
- Obesity and renoprotection
Francesca Mallamaci, Reggio Calabria, Italy
- Contrast-induced AKI in CKD patients: how much contrast agent is “safe”?
Patrick Murray, Dublin, Ireland
- Are all iron preparations equal?
Walter H. Hörl, Vienna, Austria

Hypertension, diabetes, and vascular disease

Diabetic nephropathy
- New insights into the pathogenesis of diabetic nephropathy
Katalin Susztak, New York, USA
- Models of diabetic nephropathy: in search of the holy grail
Charles Alpers, Seattle, USA
- Paradigm shifts and optimal treatment of diabetic nephropathy
Carl Eric Mogensen, Aarhus, Denmark
- Therapeutic approaches to diabetic nephropathy beyond the RAS (including SOCS; suppressors of cytokines)
Jesus Egido, Madrid, Spain

Progression of CKD and associated
cardiovascular complications
- Endothelin antagonists and renal progression
David J. Webb, Edinburgh, UK
- Effects of endothelin antagonists in CKD
René R. Wenzel, Zell am See, Austria
- The role of renalase in cardiovascular risk/pathology in CKD
Manuel Pestana, Porto, Portugal
- Vascular effects of aldosterone: role in CKD?
Ernesto L. Schiffrin, Montréal, Canada

Novel invasive strategies in antihypertensive treatment - Renal sympathetic denervation, baroreflex stimulation
- Renal denervation as antihypertensive treatment - How does it work?
Gerald F. DiBona, Iowa City, USA
- Sympathetic denervation as antihypertensive treatment - critical appraisal of first results
Johannes Mann, Munich, Germany
- Resistant hypertension – baroreflex stimulation as a new tool
Jan Menne, Hanover, Germany

Reappraisal of European Guidelines
- How to assess target organ damage – blood vessels vs. kidney?
Sadayoshi Ito, Sendai, Japan
- Blood pressue control in CKD 4-5 patients with diabetes: the ERBP guideline
Hermann Haller, Hanover, Germany
- Antihypertensive treatment in dialysis patients
Rajiv Agarwal, Indianapolis, USA
- Novel antihypertensive agents
Mustafa Arici, Ankara, Turkey

The prehypertensive kidney
- Pathophysiological renal characteristics of prehypertension
Peter W. de Leeuw, Maastricht, Netherlands
- Early markers of renal dysfunction in prehypertension
Alexander Rosenkranz, Graz, Austria
- Tubulo-interstitial changes in early hypertension and its relation to natriuresis
Jacek Manitius, Bydgoszcz, Poland
- Renal dysfunction and chronic abnormalities in prehypertension
Luis Ruilope, Madrid, Spain

End stage renal disease, dialysis

ERA-EDTA Registry session
- The Registry in 2012: a source for research and collaboration
Christoph Wanner, Würzburg, Germany
- European nephrologists' experience with the decision not to start RRT
Moniek van de Luijtgaarden, Amsterdam, Netherlands
- EQUAL study - an international study in Stage 4 CKD
Kitty Jager, Amsterdam, Netherlands
- Policies and practices of paediatric kidney transplantation across Europe
Jérome Harambat, Bordeaux, France
- Pregnancy in chronic dialysis patients - a systematic review
Marlies Noordzij, Amsterdam, Netherlands
- Timing and outcome of RRT in patients with congenital malformations of the kidney and the urinary tract
Elke Wühl, Heidelberg, Germany

Correlating International Hemodialysis
Practice Differences with Outcomes: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

- Benefits of studying differences in practice and outcomes
Bruce Robinson, Ann Arbor, USA
- Practices before and after policy changes
Werner Kleophas, Düsseldorf, Germany
- Transitions from CKD to dialysis
Christian Combe, Bordeaux, France
- Indicators related to Mineral Bone Disease
Francesca Tentori, Ann Arbor, USA
- Vascular access: Achieving better outcomes
Richard Fluck, Derby, UK
- Panel Discussion

Atherosclerotic and cardiac disease in CKD
- Features of cardiovascular disease in CKD
Ziad A. Massy, Amiens, France
- Vascular hemodynamic changes in CKD
Gérard M. London, Fleury-Mérogis, France
- Cardiovascular complications in CKD: role of oxidative stress
Kostas Siamopoulos, Ioannina, Greece
- Reducing the risk of stroke in dialysis patients
Christiane Drechsler, Würzburg, Germany

What is “good dialysis”?
- What is early start and why it should not be systematic?
Christian Combe, Bordeaux, France
- What is late start and why is it harmful?
Charles Tomson, Bristol, UK
- When to start of dialysis: guideline and reality
James Tattersal, Leeds, UK
- Target blood pressure in hemodialysis patients
Thierry Hannedouche, Strasbourg, France
- Long dialysis sessions (daily, nocturnal etc)
Ercan Ok, Izmir, Turkey

Peritoneal dialysis
- The biology of the peritoneum, what's emerging in the 21st century. Lessons to be learnt by EuTRiPD
Christoph Aufricht, Vienna, Austria
- Mechanisms of fibrosis/sclerosis and impact of PD solutions
Vedat Schwenger, Heidelberg, Germany
- Peritoneal sclerosis and clinical membrane changes - when do we need to worry?
Simon Davies, Stoke-on-Trent, UK
- Encapsulating Peritoneal Sclerosis: clinical insights and treatments options
Martin Wilkie, Sheffield, UK

The elderly patient with CKD or on dialysis

- Haemodialysis in the elderly
Antonio Santoro, Bologna, Italy
- Treatment of frail CKD patients: maximum conservative management vs timely initiation of dialysis
Pedro Ponce, Cascais, Portugal
- Protein-energy wasting in elderly dialysis patients
Peter Barany, Stockholm, Sweden
- Kidney transplantation in the elderly
Maria Alicja Dębska-Slizien, Gdansk, Poland

Salt and volume management in dialysis patients
- Improving survival in dialysis patients: salt and volume management is more important than higher uremic toxin removal
Adrian Covic, Iasi, Romania
- Improving survival in dialysis patients: higher uremic toxin removal is more important than salt and volume management!
Raymond Vanholder, Ghent, Belgium
- Bioimpedance measurements in the assessment of volume status
Martin K. Kuhlmann, Berlin, Germany
- Lung ultrasound to assess volume status in dialysis patients
Carmine Zoccali, Reggio Calabria, Italy


Highlights of the 2011 ESOT congress (in cooperation with ESOT)
- Basic and translational science highlights from ESOT 2011
Martin J. Hoogduijn, Rotterdam, Netherlands
- Clinical highlights from ESOT 2011
Keith Rigg, Nottingham, UK
- Changes to clinical practice suggested by ESOT 2011
Josep M. Campistol, Barcelona, Spain

Tolerance and predictors of transplant outcome

- Biomarkers of transplantation tolerance
Maria Hernandez-Fuentes, London, UK
- New clinical and biological correlates of kidney operational tolerance in humans
Jean Paul Soulillou, Nantes, France
- Can genotypes predict renal graft outcomes?
Lidia Ghisdal, Brussels, Belgium
- Clinical and histological predictors of long-term kidney graft survival
Eric Rondeau, Paris, France

Diagnostic approaches to the transplant kidney
- Molecular phenotypes of renal allograft rejection
Ondrej Viklicky, Prague, Czech Republic
- Towards personalized medicine in transplantation / Biomarkers in transplantation
Josep M. Grinyó, Barcelona, Spain
- Antibodies against vascular receptors in transplant recipients
Duska Dragun, Berlin, Germany
- The clinical relevance of HLA antibody detection
Frans H.J. Claas, Leiden, Netherlands

Outcomes after transplantation
- Kidney preservation and outcome after transplantation
Sarah A. Hosgood, Leicester, UK
- Impact of CKD in the outcome after non-renal transplants
Gültekin Süleymanlar, Antalya, Turkey
- Renal transplantation with expanded criteria donors (the ERBP guideline)
Uwe Heemann, Munich, Germany
- Scandiatransplant 2011
Søren Schwarz Sørensen, Copenhagen, Denmark

Complications after transplantation
- Prevention of renal progression in renal transplantation
Anke Schwarz, Hanover, Germany
- Posttransplant recurrence of primary glomerulonephritis
Claudio Ponticelli, Milan, Italy
- Metabolic syndrome, insulin resistance, and chronic allograft dysfunction
Esteban Porrini, La Laguna, Spain
- Risk factors for NODAT. Influence of immunosuppresive therapy
Marian Klinger, Wroclaw, Poland

Bone and mineral metabolism after transplantation
- The use of cinacalcet after renal transplantation
Andries Hoitsma, Nijmegen, Netherlands
- Bone metabolism in renal transplanted patients
Pieter Evenepoel, Leuven, Belgium
- Post-transplant hypophosphatemia
Wilfried Gwinner, Hanover, Germany


The Soft-Skill Masterclass
- Why did my grant application fail? Common mistakes you should avoid
Frédéric Jaisser, Paris, France
- Common pitfalls in writing a paper
Frank Eitner, Aachen, Germany
- Collaborations, intellectual property and patents - curse or blessing
Steve Harper, Bristol, UK
- How to ruin your presentation?
Jürgen Floege, Aachen, Germany


Drug-induced renal injury: the quest for sensitive biomarkers
Organized in collaboration with Innovative Medicines Initiative (IMI)

Chair: Michel Goldman, Innovative Medicines Initiative (IMI), Brussels, Belgium

- Keynote introduction: Why do we need new biomarkers for drug-kidney interaction ?
Raymond Vanholder, Ghent, Belgium
- Preclinical approaches by the PSTC consortium to support translational drug-induced kidney injury monitoring in drug development
Jonathan Phillips, Boehringer Ingelheim, Ridgefield, U.S.A.
- The Biomarkers Consortium: Prospective clinical trial design to qualify biomarkers for drug development
Irene Nunes, Merck, West Point, U.S.A.
- Acute kidney injury biomarkers in clinical practice: current status
Ralf Schindler, Berlin, Germany
- IMI project - SAFE-T: an European consortium approach to renal safety biomarkers
Stefan Sultana, Novartis, UK
- Panel Discussion
Moderator: Jean-Marc Vidal, European Medicines Agency, London, UK

Nephrotoxicity is a serious problem for drug development and current clinical standards used for the detection of acute kidney injury, serum creatinine (sCr) and blood urea nitrogen (BUN), are suboptimal. Drugs can cause histopathological lesions and functional impairment in the kidney at doses and times where no measureable changes in sCR and BUN can be detected. This has important consequences both for patient care and the development of safe and innovative drugs. To address this issue, three public-private partnerships have been formed: the Predictive Safety Testing Consortium Nephrotoxicity Working Group, the Drug Induced Kidney Injury (DIKI) working group of the Innovative Medicines Initiative (IMI) SAFE-T consortium and the Biomarkers Consortium Kidney Safety Project Team. All three partnerships conduct research designed to define thresholds and characterize the performance of the new DIKI biomarkers in order to enhance decision making in drug development. The research focuses on the various regions of the kidney, including injury to the proximal kidney tubule and the glomerulus. Clinical studies are being conducted in patients receiving standard of care treatment known to cause injuries to the kidney via different mechanisms. The data generated will be submitted to global health authorities for regulatory qualification of new biomarkers for monitoring early onset and reversal of drug-induced kidney injury. During this session, achievements and ongoing activities of the three partnerships will be presented and the complementary scope of their approaches will be discussed.


Immunonephrology Working Group
- Introduction
Mohamed Daha, Leiden, Netherlands
- Update on the ongoing programme: VALIGA
Rosanna Coppo, Turin, Italy
- A multicentre trial for the treatment of membranous nephropathy: sequential therapy of tacrolimus and rituximab
Manuel Praga, Madrid, Spain
- A European Registry for recurrent glomerular diseases after transplantation
Jürgen Floege, Aachen, Germany
- ERA-EDTA/RPS immunopathology projects
Loreto Gesualdo, Bari, Italy
- New prospectives for IWG
Mohamed Daha, Leiden, Netherlands

Working Group on Inherited Kidney Disorders
- New Insights into Inherited Renal Fanconi Syndrome
Detlef Bockenhauer, London, UK
- Disorders of Membrane Trafficking in the Kidney
Speaker to be confirmed
- Uric Acid: From GWAS to Mendelian Disorders
Olivier Bonny, Lausanne, Switzerland
- The EuroCYST initiative
Andreas Serra, Zurich, Switzerland

EUDIAL (European Dialysis Working Group)
Recommendations based on available evidence for hemodiafiltration therapy. Report of EuDial working meeting of October 2011.

Opening / welcome
Bernard Canaud, Montpellier, France

- How to define and quantify hemodiafiltration?
James Tattersall, Leeds, UK
- How to apply HDF in a safe way? Current safety standards, regulations and guidelines.
Richard Ward, Louisville, USA
- Available clinical evidence for HDF.
Menso Nube, Amsterdam, The Netherlands / Peter Blankestijn, Utrecht, The Netherlands
- EuDial, where do we go from here?
Bernard Canaud, Montpellier, France

EURECA-m (EUropean REnal and CArdiovascular Medicine) Working Group
- Pulmonary hypertension in CKD: a neglected complication?
Alan G. Jardine, Glasgow, UK
- Ultrafiltration in heart failure: experience or evidence-based?
Enrico Fiaccadori, Parma, Italy
- The new dimension of hypertension: short term and visit to visit BP variability
Gianfranco Parati, Milan, Italy
- Coronary calcium quantification: a useful surrogate in clinical research? A reasonable biomarker in clinical practice?
Gérard M. London, Fleury-Mérogis, France

EUTox Working Group
Handling the patient with CKD: can we do more than dialyse?
- Improve early screening. CKD markers
Harald Mischak, Hannover, Germany
- Prevent fibrosis and CKD progression. New pathways and putative therapeutic targets
Alberto Ortiz, Madrid, Spain
- Alternative treatments in CKD
Raymond Vanholder, Ghent, Belgium
- New methods to treat CKD: the application of hydrophobic media in extracorporeal systems for removal of uremic toxins
Joachim Jankowski, Berlin, Germany
- Endothelial markers after transplantation
Henri Vacher-Coponat, Marseille, France


Rheumatology for nephrologists

May 24, 2012 – 8.30-12.30

Chairs: Hans-Joachim Anders, Munich, Germany and David Jayne, Cambridge, UK

- Welcome and introduction
Hans-Joachim Anders, Munich, Germany and David Jayne, Cambridge, UK
- Joint pain in CKD patients: When do we need a joint aspirate?
Hendrik Schulze-Koops, Munich, Germany
- Proteinuria in the patient with arthritis
Volker Vielhauer, Munich, Germany
- The 2012 "standard of care" in lupus nephritis – referral, drugs and monitoring
Frédéric A. Houssiau, Brussels, Belgium
- Non-renal flares in lupus nephritis patients – new options
Falk Hiepe, Berlin, Germany
- Antiphospholipid antibodies and the kidney
Ricard Cervera, Barcelona, Spain
- B cell targeted therapy in nephritis, all hype and no substance?
David Jayne, Cambridge, UK
- ANCA-associated vasculitis - an update on therapeutic strategies
Alan Salama, London, UK

Peritoneal Dialysis Workshop - in cooperation with EuroPD

May 24, 2012 – 8.30-12.30

Chair: Nicholas Topley, Cardiff, UK

- New insights in pharmacokinetics and pharmacodynamics of antibiotics: implications for the treatment of peritonitis
An De Vriese, Bruges, Belgium
- Survival on PD and HD: what do we know?
James Heaf, Herlev, Denmark
- Catheter placement: do's and dont's
Alain Slingeneyer, Montpellier, France
- Optimal and individualised PD prescription: the ERBP viewpoint
Wim Van Biesen, Ghent, Belgium
- Biocompatibility revisited: is it relevant in 2012?
Nicholas Topley, Cardiff, UK
- Membrane pathophysiology, EMT and MicroRNA's as potential therapeutic targets
Donald Fraser, Cardiff, UK
- Animal models revisited: what do they really tell us about the peritoneum
Olivier Devuyst, Zurich, Switzerland
- Peritoneal membrane physiology and function: insights from cohort studies
Simon Davies, Stoke-on-Trent, UK

Clinical questions for managing Nephrolithiasis - in cooperation with the EAU Section of Urolithiasis (EULIS)

May 24, 2012 – 13.00-17.00

Chairs: Giovanni Gambaro, Rome, Italy and Noor Buchholz, London, UK

- What do we ask the radiologist? - What can the radiologist tell us?
Kim Hovgaard Andreassen, Fredericia, Denmark
- What do we learn from the stone’s analysis?
Michel Daudon, Paris, France
- When and why do we suspect a genetic disorder in a patient with stones?
Giovanni Gambaro, Rome, Italy
- When and why do we suspect a tubular disorder in a patient with stones?
Robert Unwin, London, UK
- How do we interpret and manage hypercalciuria?
Philippe Jaeger, London, UK
- How do we interpret the results of urine analysis?
Martino Marangella, Turin, Italy
- How do we manage patients’ diet?
Alberto Trinchieri, Lecco, Italy
- What does the urologist ask the nephrologist?
Noor Buchholz, London, UK

Renal Pathology course

May 24, 2012 – 13.00-17.00

Chairs: Kerstin Amann, Erlangen, Germany and Sandrine Florquin, Amsterdam, Netherlands

- New insights in C3 nephropathy
Terry Cook, London, UK
- Critical review of the ISN/RPS classification of lupus nephritis
Ian Roberts, Oxford, UK
- Update in renal transplantation
Heinz Regele, Vienna, Austria
- Monoclonal deposit diseases
Eric Steenbergen, Nijmegen, Netherlands








Il contenuto di questa pagina richiede una nuova versione di Adobe Flash Player.

Scarica Adobe Flash Player